Bills authored by Sen. Rob Standridge, R-Norman, also a pharmacist, pertaining to pharmacists, pharmacies, and/or pharmaceuticals
2021
• Senate Bill 120. To create the Prescription Drug Safety and Cost Reduction Pilot Program Act. Would require the Oklahoma Health Care Authority (OHCA) to submit an application to the federal government to establish a prescription drug importation program for Oklahoma’s Medicaid program, and require the OHCA to identify and make certain drugs available to participating pharmacies.
Assigned 2/02/21 to the Senate Health and Human Services Committee, of which Standridge is a member. No further activity on the measure has been recorded.
• SB 370. Relating to powers and duties of the State Board of Pharmacy. Referred to S H&HS Committee on 2/02/2021. No further activity recorded.
• SB 392. Directing health insurers to provide direct payment or reimbursement to a licensed pharmacist under certain conditions. Passed Senate 42-2; Standridge voted “yea”. Transmitted to House of Representatives.
• SB 538. An Act relating to prescription drugs; creating the Oklahoma Patient Right to Know Act. Do Pass recommendation by the Senate Retirement and Insurance Committee.
• SB 605. Provides that a licensed practitioner with appropriate prescriptive authority would not be criminally or civilly liable solely for prescribing or dispensing an opioid drug if the amount does not exceed the maximum daily dosage amounts.
Referred to S H&HS Committee, which endorsed the measure 8-2; Standridge voted “aye”. Passed Senate 35-8; Standridge “yea”.
• SB 696. Authorizing licensed pharmacists to compound certain non-sterile preparations for specified individuals under certain conditions. Referred to S H&HS Committee, which endorsed it 10-0; Standridge “aye”. Senate passed the bill 45-0; Standridge “yea”. Measure transmitted to HoR.
• SB 697. Requiring wholesale drug distributors to make adequate provisions for the return of certain outdated prescription drugs. Do Pass S H&HS Committee by an 11-0 vote; Standridge “aye”. Passed Senate 44-1; Standridge “yea”. Transmitted to HoR.
• SB 888. The committee substitute for SB 888 creates a registration process for pain management clinics in the state. One of its provisions decrees that “a prescriber who issues a prescription for a controlled dangerous substance shall not dispense the controlled dangerous substance pursuant to such prescription.”
Do Pass S H&HS Committee 10-0; Standridge “aye”. Passed Senate 42-2; Standridge “yea”. Transmitted to HoR.
2020
• Senate Bill 940. The “Prescription Drug Safety and Cost Reduction Importation Pilot Program Act”.
Do Pass, Senate Health and Human Services Committee (no recorded vote available on Senate website) and then Do Pass, Senate Appropriations Committee. Passed Senate 41-4; Standridge voted “yea”. Died in HoR.
• SB 1221. Would have provided an exemption to the electronic prescription requirement for Schedule II substances, for practitioners who administer the drug to a patient in a hospice program. Referred to S H&HS Committee; no further activity recorded.
• SB 1272. Directing the Oklahoma Health Care Authority to study the feasibility of integrating pharmacogenomic testing into the state Medicaid program for patients prescribed anti-psychotic drugs. Referred to S H&HS Committee; no further activity recorded.
• SB 1342. Would prohibit a drug wholesaler from preventing a licensed pharmacy under contract with the wholesaler “from purchasing drugs that the wholesaler sells if the pharmacy is in compliance with all applicable state and federal laws.”
Do Pass, S H&HS Committee (no recorded vote available online). Passed Senate 30-17; Standridge voted “yea”. Died in the House of Representatives.
• SB 1502. Pharmacies that conduct significant compounding would be authorized to utilize up to two specialized technicians, who would not be counted toward the technician-to-pharmacist ratio. Also would authorize the State Board of Pharmacy to inspect an out-of-state licensed pharmacy, and would require hospital pharmacies to maintain a technician-to-pharmacist ratio of no more than 4-to1.
Do Pass, S H&HS Committee (recorded vote not available on Senate website). Approved 32-13 in Senate floor vote; Standridge “yea”. Died in HoR.
• SB 1512. Would provide protection to licensed practitioners prescribing opioids from prosecution or disciplinary action for prescribing an opioid drug in accordance with current law. Do Pass, Senate Judiciary Committee; approved by Senate 44-0; Standridge voted “aye”. Died in HoR.
• SB 1558. Would require each health benefit plan provider to publish detailed information pertaining to all forms of remuneration derived from rebates or other forms of incentives received from purchases of prescription drugs or medical devices. Referred to Senate Retirement and Insurance Committee; no further activity recorded.
• SB 1620. The Oklahoma Patient Right to Know Act. Would authorize pharmacists to submit a request in writing from a patient for information about the specific allocation of the dollar amount of the retail price provided to the insurer, manufacturer, wholesale drug distributor and pharmacy benefit manager for the drug or drugs being dispensed.
Do Pass, Senate Retirement and Insurance Committee. To Senate calendar but no floor vote.
• SB 1912. Would direct the State Department of Health to design a wholesale prescription drug importation program in consultation with interested stakeholders and appropriate federal officials. Referred to S H&HS Committee and then to S Appropriations Committee; no further activity recorded.
• SB 1918. Would provide immunity from civil or criminal liability to practitioners who prescribe an opioid if the prescribed dosage does not exceed the maximum dosage amounts provide by the drug manufacturer and the U.S. Food and Drug Administration, and the practitioner obtains a signed statement from the patient. Licensed pharmacists would be provided with such immunity, too, provided the pharmacist does not dispense a dosage that exceeds recommended dosage amounts and verbally confirms the signed statement with the patient.
Do Pass, S H&HS Committee, 11-0; Standridge voted “aye”. No further activity recorded.
• House Bill 2617, sponsored in the Senate by Standridge. Legislation pertaining to pharmacy consultants. Passed House of Representatives 3/10/2020. Assigned to Senate Retirement and Insurance Committee; no further activity recorded.
• House Bill 3791, sponsored in the Senate by Standridge. To allow pharmacists to substitute a prescribed biological product for an FDA-approved interchangeable substitute, if the prescribing physician allowed the substitution and the pharmacy informed the patient of the substitution.
Passed HoR and referred to S H&HS Committee; no further activity recorded.
2019
• SB 497. An Act relating to health insurance, to require an insurer to provide payment or reimbursement to a pharmacist in certain circumstances. Passed Senate 47-0; Standridge “yea”. Died in HoR.
• SB 856. To expand certain powers and duties of the State Board of Pharmacy. Would ensure that all Oklahoma-licensed pharmacies, inside the outside the state, are in compliance with all laws and regulations governing pharmacies, including regs related to technician-to-pharmacist ratio “which shall not exceed 2-to-1” and storage requirements for medications until received by the patient.
Do Pass, S H&HS Committee; Standridge “aye”. Senate approved 47-0; Standridge “yea”. Died in HoR.
• HB 1155, sponsored in the Senate by Standridge. Provides that if a practitioner believes after one year of continuous treatment that the patient is in compliance with a pain-management agreement, the practitioner is authorized to set the review of the treatment plan at 4- or 6-month intervals and issue prescriptions for the patient as necessary.
Passed HoR. Do Pass, S H&HS Committee, 12-0; Standridge “yea”. Passed Senate 44-0; Standridge “aye”. Signed into law by Governor.
2018
• SB 1371. Would require the State Board of Pharmacy to ensure that all pharmacies licensed by the State of Oklahoma, inside and outside the state, follow all laws and regulations governing pharmacy, including technician to pharmacist ratios and storage requirements for medications until they’re received by the patient.
Do Pass, S H&HS Committee 10-0; Standridge “aye”. Passed Senate 42-0; Standridge “yea”. Died in HoR.
• SB 1381. To create the “Prescription Drug Safety and Cost Reduction Pilot Program Act” to allow importation of prescription drugs from Canada. Referred to S H&HS Committee; no further activity recorded.
• SB 1483. Would have decreed that only a licensed practitioner could dispense dangerous drugs to patients, and only for the expressed “purposes of treating postoperative pain, providing palliative care and dispensing professional samples…” Referred to S H&HS Committee; no further activity recorded.
• SB 1511. Regulation of “specialty pharmacies”. Assigned to S H&HS Committee; no further activity recorded.
• SB 1573. Relating to pharmacy benefit plans. It would have prohibited a pharmacy benefits manager from requiring a covered individual to obtain prescription drugs from a mail-order pharmacy “or through the mail or other common carrier”.
SB 1573 also would have forbidden a pharmacy benefits manager from “deny[ing] a pharmacy the opportunity to participate in the PBM’s network if the pharmacy is willing to accept the terms and condition that the PBM has established,” or “prohibit[ing] a covered individual from utilizing the pharmacy of their choice, provided the pharmacy participates in the PBM’s network..”
Died in the Senate Judiciary Committee.
2017
• SB 659. To require certain health benefit plans to authorize certain cost-sharing amount for prescription drugs in certain circumstances; prohibiting prorating certain fees; authorizing a pharmacist or pharmacy to override health care plan’s denial of certain coverage; providing certain immunity to pharmacists in certain situations.
Referred to S Retirement and Insurance Committee; no further activity recorded.
• SB 685. Broadening authority of the State Board of Pharmacy over certain activities. Referred to S H&HS Committee; no further activity recorded.
• SB 771. Relates to dispensing controlled dangerous drugs. “Only a licensed practitioner may dispense dangerous drugs to such practitioner’s patients, and only for the expressed purpose of serving the best interests and promoting the welfare of such patients, including in connection with a surgical procedure … or in the administration of a controlled clinical trial.”
Do Pass, S H&HS Committee (no recorded vote). No further activity recorded.
• SB 784. It addressed powers of the State Board of Pharmacy. Among them, it would have given the board authority to “approve pilot projects designed to utilize new or expanded technology or processes and provide patients with better pharmacy products or provide pharmacy services in a more safe and efficient manner.”
Assigned to S H&HS Committee, where it received a “do pass” recommendation (no recorded vote). Passed the Senate, 45-0; Standridge voted “yea”. Passed the HoR. Vetoed by the Governor.
• HB 2039, sponsored in the Senate by Standridge. Authorizing licensed pharmacists to prescribe and dispense naloxone. “No dispensing protocol shall be required,” the bill stipulated.
Do Pass, S H&HS Committee (no recorded vote). Approved by Senate 43-0; Standridge “yea”. Signed into law by Governor Fallin.
2016
• SB 1150. An act relating to pharmacy; definitions; updating statutory references; continuing education requirements; license renewal; sales, manufacturing and packaging of dangerous drugs; unlawful acts; revocations or suspensions of licenses; alternative methods of meeting certain requirements.
Do Pass, S H&HS Committee (no recorded vote). Approved by the Senate, 43-2; Standridge voted “yea”. Approved by Governor Fallin.
2015
• SB 787. Amending the Oklahoma Pharmacy Act by modifying, adding and removing several definitions.
Do Pass, S H&HS Committee (no recorded vote). Approved by Senate, 42-2; Standridge voted “yea”. Bill signed into law by Governor Fallin.
2014
• SB 1219. Would prohibit sales of the so-called “morning-after” contraceptive to individuals under the age of 17 without a prescription. Do Pass, S H&HS Committee (no recorded vote). Approved by Senate, 33-11; Standridge voted “yea”. Died in House Committee on Public Health.
• SB 1243. To require nursing homes to obtain an annual registration from the director of the Oklahoma State Bureau of Narcotics and Dangerous Drug Control in order to dispense controlled dangerous substances for scientific purposes. (The registration fee at that time was $140.)
Do Pass, S H&HS Committee. Passed Senate, 44-0; Standridge “yea”. Died in the House Committee on Public Health.
• SB 1267. To require pain management clinics that “prescribe, administer, distribute or dispense controlled dangerous substances” to obtain registration from the director of the OBNDD. Assigned to the S H&HS Committee; no further activity recorded.
• HB 2666, sponsored in the Senate by Standridge. Amending the Uniform Controlled Dangerous Substances Act. Among its provisions: “Naloxone … may be dispensed or sold by a pharmacy without a prescription; … however, it shall be dispensed or sold only by, or under the supervision of, a licensed pharmacist.”
Do Pass, S H&HS Committee (no recorded vote). Approved by Senate, 41-2; Standridge “yea”. Signed by Governor.
• HB 2100, sponsored in the Senate by Standridge. Creating oversight, licensing and regulation of Pharmacy Benefits Managers. Approved by Senate, 41-3; Standridge voted “yea”. Signed by Governor.
2013
• SB 522. Would have authorized regulation of non-resident pharmacies through the state Board of Pharmacy, and required non-resident pharmacies to submit certain documents and provide an additional fee of $100 to cover the newly associated costs of administrative review.
Do Pass, S H&HS Committee (no recorded vote). Passed Senate, 42-0, on third reading; Standridge voted “yea”. Amended by HoR and returned to Senate. Amendments rejected, sent to joint conference committee. Conference committee report approved by Senate, 34-10; Standridge “yea”. CCR never brought to the House floor for a vote.
• HB 2086, sponsored in the Senate by Standridge. Would have directed the Oklahoma Health Care Authority to conduct a cost/benefit analysis of the SoonerCare (Medicaid) prescription plan to determine whether it would be “more beneficial to keep the plan within” the OHCA or to seek competitive bids on the plan.
Passed the HoR, 93-0, then assigned to the H&HS Committee in the Senate; no further activity recorded.
Bills Authored by Standridge that Pertain to Narcotics, Opioids and Law Enforcement
• SB 1146, filed in 2020. Would add three drugs to the list of Schedule I controlled substances. Passed Senate 45-1; Standridge “yea”. Transmitted to House of Representatives, where it died.
• Senate Bill 1197, filed in 2020. Would have modified penalties for possession of methamphetamine. Assigned to Public Safety Committee and then Appropriations Committee in Senate; no further activity recorded.
• SB 1734, filed in 2020. Would clarify the permissible THC concentration in industrial hemp. Do Pass Senate Public Safety Committee. No further activity recorded.
• SB 166, introduced in 2019. Adding substances to the list of Schedule I and II controlled dangerous substances. Passed Senate, 42-1 (recorded vote not available online). Passed HoR, signed into law by Governor.
• SB 238, authored in 2019. Requiring any product that contains cannabidiol to carry a label showing the country of origin and whether the cannabidiol is synthetic or natural. Do Pass, S H&HS Committee by a vote of 13-0; Standridge “aye”. Passed Senate 42-2; Standridge “yea”. Amended by HoR, approved by Senate, 44-1; Standridge “yea”. Signed into law by Governor Fallin.
• SB 937, introduced in 2018. Allowing the director of the Oklahoma Bureau of Narcotics and Dangerous Drugs Control (OBNDD) to authorize tribal law enforcement agencies to access the central repository. Passed Senate 40-4; Standridge “yea”. Passed HoR, signed by Governor.
• SB 939, filed in 2018. Added certain forms of Ritalin to the list of Schedule II drugs. Do Pass, S H&HS Committee; Standridge “yea”. Passed Senate 43-0; Standridge “aye”. Passed HoR, signed by Governor.
• SB 940, introduced in 2018. Adds certain forms of fentanyl and another drug to the list of Schedule I drugs. Referred to S H&HS Committee, which endorsed it 12-0; Standridge “aye”. Passed by Senate 43-0; Standridge “yea”. Signed by Governor.
• SB 684, filed in 2017. Authorizing the State Board of Pharmacy to collaborate with the Oklahoma State Bureau of Investigation “for the purposes of carrying out the provisions of the Anti-Drug Diversion Act”. Referred to S H&HS Committee; no further activity recorded.
• SB 770, filed in 2017. Among other things, it increased the hours of training required of reserve special agents of the OBNDD: from 160 to 240. Referred to the S H&HS Committee, where it received a “do pass” recommendation; Standridge voted “aye”. Passed Senate; Standridge voted “yea”. Sent to House/Senate conference committee. Conference Committee Report approved by Senate; Standridge voted “yea”. Approved by Governor.
• SB 800, filed in 2017. An agent of the OBNDD would be authorized to use information in the central repository “where such use is appropriate to the proper performance of his/her officials duties, including prevention of the misuse and abuse of controlled dangerous substances.”
Do Pass, S H&HS Committee (no recorded vote). Failed on Senate floor vote, 16-29.
• HB 2665, filed in 2014 and sponsored in the Senate by Standridge. Pertaining to the Anti-Drug Diversion Act. Allows the director of the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control to disclose information related to Oklahoma’s prescription-monitoring-program to prescription monitoring programs of other states if a reciprocal data-sharing plan is in place.
Do Pass, S H&HS Committee (no recorded vote). Passed Senate, 39-2; Standridge voted “yea”. Signed by Governor.
Miscellaneous Measures Introduced by Standridge
• Senate Joint Resolution 22 filed this year, calling for a convention of state under Article V of the U.S. Constitution, to propose a constitutional amendment decreeing that if the U.S. House of Representatives impeaches a sitting President but the U.S. Senate does not vote to convict, the President “shall be allowed an additional single term as President over the two-term limit” that’s imprinted in the Constitution.
Referred to the Senate Rules Committee.
• SB 498, filed in 2019 to prohibit the Oklahoma Health Care Authority from converting the state’s Medicaid program to a managed care system “without the express approval of the Legislature.” Referred to the Senate’s Rules Committee and then the Appropriations Committee. No further activity recorded.
• SB 1250, filed in 2020. Would require vapor products containing vitamin E acetate to bear a label stating so and warning users about “the potentially harmful and fatal effects of inhaling vitamin E acetate.”
Referred to S H&HS Committee. No further activity recorded.